
CLAIMS

1. Use of a compound of the following structure in manufacture of a medicament for treating cancer:



wherein X is O;

R_1 is a hydrogen;

each of R_2, R_3, R_4, R_5, and R_6 is independently a hydrogen or a hydroxyl;

R_8 and R_9 are each hydrogen;

z is 1 or 2; and

wherein the compound is to be administered at a dose of 0.1 mg/day to 1 g/day.

2. The use of claim 1, wherein R_3 and R_4 are each -OH.

3. The use of claim 1, wherein R_2 and R_3 are each -OH.

4. The use of claim 1, wherein z is 2 and R_8 and R_9 are each -H.

5. The use of claim 1,

wherein z is 2;

R_1, R_4, R_5, R_6, R_8 and R_9 are each -H; and

R_2 and R_3 are each -OH.

6. The use of claim 1, wherein


R_1, R_2, R_5, R_6, R_8, and R_9 are each -H;

R_3 and R_4 are each -OH;

X is O; and

z is 2.


7. The use of claim 1, wherein the compound has the following structure:



or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate or mixture of stereoisomers thereof.

8. Use of a compound as defined in claim 1 in the manufacture of a medicament for treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), breast cancer, and colon cancer.

9. The use of claim 8, wherein the compound has the following structure:



or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate or mixture of stereoisomers thereof.

10. The use of claim 8, wherein one or more additional therapeutic agents comprising anticancer agents or chemotherapeutic agents are to be further administered.